Paclitaxel, ifosfamide, and nedaplatin (TIN) salvage chemotherapy for patients with advanced germ cell tumors

International Journal of Urology

Volumn 14, Issue 6, 2007, Pages 527-531

  Nonomura, Norio ^a,c   Oka, Daizo ^a   Nishimura, Kazuo ^a   Nakayama, Masashi ^a   Inoue, Hitoshi ^a   Mizutani, Yoichi ^b   Miki, Tsuneharu ^b   Okuyama, Akihiko ^a  

^a OSAKA UNIVERSITY   (Japan)

^b KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^c OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Germ cell tumor; Ifosfamide; Nedaplatin; Paclitaxel; Salvage chemotherapy

Indexed keywords

BLEOMYCIN; CISPLATIN; DEXAMETHASONE; DIPHENHYDRAMINE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; IFOSFAMIDE; IRINOTECAN; MESNA; NEDAPLATIN; PACLITAXEL; RANITIDINE; VINBLASTINE;

ADULT; ADVANCED CANCER; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER SURGERY; CLINICAL ARTICLE; CONTINUOUS INFUSION; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FATIGUE; FOLLOW UP; GASTRITIS; GERM CELL TUMOR; GROWING TERATOMA SYNDROME; HUMAN; HYDRONEPHROSIS; JAPANESE; LEUKOCYTE; LEUKOPENIA; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; MEDIASTINUM; MOTOR NEUROPATHY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; SALVAGE THERAPY; SENSORY NEUROPATHY; TERATOMA; TESTIS CANCER; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADULT; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; IFOSFAMIDE; KIDNEY FAILURE, ACUTE; MALE; NEOPLASMS, GERM CELL AND EMBRYONAL; ORGANOPLATINUM COMPOUNDS; PACLITAXEL; SALVAGE THERAPY; TESTICULAR NEOPLASMS; TREATMENT OUTCOME;

EID: 34250844919     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2006.01702.x     Document Type: Article

References (21)

1. Einhorn LH. Curing metastatic testicular cancer. Proc. Natl Acad. Sci. USA 2002 99 : 4592 5.
2. Einhorn EH. Testicular cancer: an oncological success story. Clin. Cancer Res. 1997 3 : 2630 2.
3. Farhat F, Culine S, Theodore C et al. Cisplatin and ifosfamide with either vinblastine or etoposide as salvage therapy for refractory or relapsing germ cell tumor patients: the Institut Gustave Roussy experience. Cancer 1996 77 : 1193 7.
4. McCaffrey JA, Mazumdar M, Bajorin DF et al. Ifosfamide- and cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumors: response and survival. J. Clin. Oncol. 1997 15 : 2559 63.
5. Loehrer PJ Gonin R, Nichols CR et al. Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor. J. Clin. Oncol. 1998 16 : 2500 4.
6. Pico JL, Rosti G, Kramar A et al. A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours. Ann. Oncol. 2005 16 : 1152 9.
7. Motzer RJ, Sheinfeld J, Mazumdar M et al. Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer. J. Clin. Oncol. 2000 18 : 2413 18.
8. Kawai K, Miyazaki J, Tsukamoto S et al. Paclitaxel, ifosfamide and cisplatin regimen is feasible for Japanese patients with advanced germ cell cancer. Jpn. J. Clin. Oncol. 2003 33 : 127 31.
9. International Germ Cell Cancer Collaborative Group. International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. J. Clin. Oncol. 1997 15 : 594 603.
10. Japanese Urological Association/The Japanese Society of Pathology. General Rules for Clinical and Pathological Studies on Testicular Tumors, 3rd edn. Kanehara, Tokyo, 2005.
11. National Cancer Institute. National Cancer Institute Common Toxicity Criteria (Version 3.0). 2003. [Cited 3 10 2005.] Available from URL: http://ctep.cancer.gov/reporting/ctc.html).
12. Bokemeyer C, Schmoll HJ, Natt F et al. Preliminary results of a phase I/II trial of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer. J. Cancer Res. Clin. Oncol. 1994 120 : 754 7.
13. Motzer RJ, Bajorin DF, Schwartz LH et al. Phase II trial of paclitaxel shows antitumor activity in patients with previously treated germ cell tumors. J. Clin. Oncol. 1994 12 : 2277 83.
14. Motzer RJ, Chou TC, Schwartz L et al. Paclitaxel in germ cell cancer. Semin. Oncol. 1995 22 : 12 15.
15. Motzer RJ, Mazumdar M, Sheinfeld J et al. Sequential dose-intensive paclitaxel, ifosfamide, carboplatin, and etoposide salvage therapy for germ cell tumor patients. J. Clin. Oncol. 2000 18 : 1173 80.
16. Rick O, Beyer J, Schwella N et al. Assessment of amifostine as protection from chemotherapy-induced toxicities after conventional-dose and high-dose chemotherapy in patients with germ cell tumor. Ann. Oncol. 2001 12 : 1151 5.
17. Akaza H, Togashi M, Nishio Y et al. Phase II study of cis-diammine (glycolato) platinum, 254-S, in patients with advanced germ-cell testicular cancer, prostatic cancer, and transitional-cell carcinoma of the urinary tract. 254-S Urological Cancer Study Group. Cancer Chemother. Pharmacol. 1992 31 : 187 92.
18. Fukuda M, Shinkai T, Eguchi K et al. Phase II study of (glycolate-O,O') diammineplatinum (II), a novel platinum complex, in the treatment of non-small-cell lung cancer. Cancer Chemother. Pharmacol. 1990 26 : 393 6.
19. Desoize B, Madoulet C. Particular aspects of platinum compounds used at present in cancer treatment. Crit. Rev. Oncol. Hematol. 2002 42 : 317 25.
20. Miki T, Mizutani Y, Nonomura N et al. Irinotecan plus cisplatin has substantial antitumor effect as salvage chemotherapy against germ cell tumors. Cancer 2002 95 : 1879 85.
21. Berger T, Malayeri R, Doppelbauer A et al. Neurological monitoring of neurotoxicity induced by paclitaxel/cisplatin chemotherapy. Eur. J. Cancer 1997 33 : 1393 9.